4 results
Primary objective:To compare the efficacy of iberdomide, daratumumab and dexamethasone (IberDd) to that of daratumumab, bortezomib and dexamethasone (DVd) in terms of progression-free survival (PFS) in subjects with RRMMSecondary objectives:• In…
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…
Primary objective: To evaluate progression-free survival
To assess the antibody response after SARS-CoV-2 vaccination in people >=16 years and children with Down Syndrome. Part 2To assess the antibody response after a third SARS-CoV-2 vaccination in adults and children with Down Syndrome and to…